The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia

PHASE3CompletedINTERVENTIONAL
Enrollment

806

Participants

Timeline

Start Date

December 23, 2020

Primary Completion Date

May 25, 2022

Study Completion Date

January 16, 2023

Conditions
Hyperlipemia
Interventions
DRUG

JS002

JS002: 150mg(1mL) Q2W; Placebo 1mL Q2W.

DRUG

Placebo

JS002: 300mg(2mL) Q4W; Placebo 2mL Q4W.

Trial Locations (57)

15000

The Fourth Affiliated Hospital of Harbin Medical University, Haerbin

100000

Beijing Anzhen Hospital, Capital Medical University, Beijing

Beijing Chaoyang Hospital, Capital Medical University, Beijing

Beijing Tongren Hospital Affiliated to Capital Medical University City:Beijing, Beijing

China-Japan Friendship Hospital, Beijing

Peking University Third Hospital, Beijing

110000

The People's Hospital of Liaoning Provincial, Shenyang

110020

General Hospital of the PLA Northern Theater Command, Shenyang

116000

The central hospital of Dalian, Dalian

121000

The First Affiliated Hospital of Jinzhou Medical University, Jinzhou

130000

First Hospital of Jilin University, Changchun

130033

China-Japan Union Hospital of Jilin University, Changchun

163316

Daqingshi People's Hospital, Daqing

200000

Huashan Hospital Affiliated to Fudan University, Shanghai

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

Shanghai Changhai Hospital, Shanghai

Shanghai East Hospital, Shanghai

210009

Zhongda Hospital Southeast Universty, Nanjing

213000

The Second People's Hospital of Changzhou, Changzhou

221000

Affiliated Hospital of Xuzhou Medical University, Xuzhou

225000

Northern Jiangsu People's Hospital, Yangzhou

233000

The First Affiliated Hospital of Bengbu Medical College, Bengbu

250000

Jinan Central Hospital, Jinan

Qilu Hospital of Shandong University, Jinan

300000

Teda International Cardiovascular Hospital, Tianjin

Tianjin First Central Hospital, Tianjin

Tianjin People's Hospital, Tianjin

318000

Taizhou Hospital of Zhejiang Province, Taizhou

325000

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

330000

The First Hospital of Nanchang, Nanchang

The Second Affiliated Hospital of Nanchang University, Nanchang

350000

The 900 Hospital of the Joint Service Support Force of the People's Liberation Army of China, Fuzhou

The First Affiliated Hospital of Fujian Medical University, Fuzhou

400000

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

410000

The Third Xiangya Hospital of Central South University, Changsha

410100

The Second Xiangya Hospital of Central South University, Changsha

430000

Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan

434000

Jingzhou Central Hospital, Jingzhou

450000

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

471000

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang

510000

Guangdong General Hospital, Guangzhou

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

518000

Peking University Shenzhen Hospital, Shenzhen

530000

The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning

550000

Affiliated Hospital of Guizhou Medical University, Guiyang

570100

Hainan General Hospital, Haikou

610000

West China Hospital of Sichuan University, Chengdu

710000

The First Affiliated Hospital of the Air Force Medical University, Xian

The Second Affiliated Hospital of Xi'an Jiaotong University, Xian

712000

Xianyang Hospital of Yan 'an University, Xianyang

730000

Lanzhou University Second Hospital, Lanzhou

The First Hospital of Lanzhou University City:Lanzhou, Lanzhou

5100000

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

050000

The First Hospital of Hebei Medical University, Shijiazhuang

The Second Hospital of Hebei Medical University, Shijiazhuang

030000

First Hospital of Shanxi Medical University, Taiyuan

Shanxi Provincial People's Hospital, Taiyuan

All Listed Sponsors
lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER

NCT04781114 - The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia | Biotech Hunter | Biotech Hunter